Transferrin receptor 1 (TfR1) mediated brain delivery of antibodies could become important for increasing the efficacy of emerging immunotherapies in Alzheimer's disease (AD). This evidence concerns the gene TFRC and early-onset autosomal dominant Alzheimer disease.